Antiphospholipid Antibodies and Recurrent Thrombotic Events: Persistence and Portfolio | Zendy

Colum Amory | Zendy; Steven R. Levine | Zendy; Robin L. Brey | Zendy; Mulugeta Gebregziabher | Zendy; Stanley Tuhrim | Zendy; Barbara C. Tilley | Zendy; Ann-Catherin C. Simpson | Zendy; Ralph L. Sacco | Zendy; J.P. Mohr | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Antiphospholipid Antibodies and Recurrent Thrombotic Events: Persistence and Portfolio

Author(s) -

Colum Amory,

Steven R. Levine,

Robin L. Brey,

Mulugeta Gebregziabher,

Stanley Tuhrim,

Barbara C. Tilley,

Ann-Catherin C. Simpson,

Ralph L. Sacco,

J.P. Mohr

Publication year - 2015

Publication title -

cerebrovascular diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.221

H-Index - 104

eISSN - 1421-9786

pISSN - 1015-9770

DOI - 10.1159/000441362

Subject(s) - medicine , hazard ratio , antiphospholipid syndrome , stroke (engine) , cardiology , myocardial infarction , proportional hazards model , thrombosis , pulmonary embolism , confidence interval , mechanical engineering , engineering

There are very limited prospective data on the significance of persistent antiphospholipid antibodies (aPL) and recurrent thrombo-occlusive events (TOEs). We investigated the prognostic value of (1) 2 newer aPL assays, (2) an aPL portfolio and (3) persistent aPL positivity following stroke.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research